CN109568340B - Medicine for treating stomatitis - Google Patents
Medicine for treating stomatitis Download PDFInfo
- Publication number
- CN109568340B CN109568340B CN201811503159.XA CN201811503159A CN109568340B CN 109568340 B CN109568340 B CN 109568340B CN 201811503159 A CN201811503159 A CN 201811503159A CN 109568340 B CN109568340 B CN 109568340B
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- patch
- medicament
- treating stomatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 208000003265 stomatitis Diseases 0.000 title claims abstract description 44
- 229940079593 drug Drugs 0.000 title claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 18
- 239000008101 lactose Substances 0.000 claims abstract description 18
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 44
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 33
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 23
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 22
- 229930003270 Vitamin B Natural products 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 21
- 235000019156 vitamin B Nutrition 0.000 claims description 21
- 239000011720 vitamin B Substances 0.000 claims description 21
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 20
- 239000001508 potassium citrate Substances 0.000 claims description 15
- 229960002635 potassium citrate Drugs 0.000 claims description 15
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 15
- 235000011082 potassium citrates Nutrition 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 12
- 229960002477 riboflavin Drugs 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 235000019482 Palm oil Nutrition 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 11
- 229930003756 Vitamin B7 Natural products 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 229930003316 Vitamin D Natural products 0.000 claims description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 11
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 11
- 239000011790 ferrous sulphate Substances 0.000 claims description 11
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 11
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 11
- 239000002540 palm oil Substances 0.000 claims description 11
- 229940055726 pantothenic acid Drugs 0.000 claims description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims description 11
- 239000011713 pantothenic acid Substances 0.000 claims description 11
- 235000019192 riboflavin Nutrition 0.000 claims description 11
- 239000002151 riboflavin Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 235000019155 vitamin A Nutrition 0.000 claims description 11
- 239000011719 vitamin A Substances 0.000 claims description 11
- 235000011912 vitamin B7 Nutrition 0.000 claims description 11
- 239000011735 vitamin B7 Substances 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 235000019166 vitamin D Nutrition 0.000 claims description 11
- 239000011710 vitamin D Substances 0.000 claims description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 229940045997 vitamin a Drugs 0.000 claims description 11
- 229940046008 vitamin d Drugs 0.000 claims description 11
- 235000021119 whey protein Nutrition 0.000 claims description 11
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 11
- 229960001763 zinc sulfate Drugs 0.000 claims description 11
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 10
- 235000012907 honey Nutrition 0.000 claims description 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 10
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 10
- 235000011009 potassium phosphates Nutrition 0.000 claims description 10
- 235000019168 vitamin K Nutrition 0.000 claims description 10
- 239000011712 vitamin K Substances 0.000 claims description 10
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 10
- 229940046010 vitamin k Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000005715 Fructose Substances 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 229940088594 vitamin Drugs 0.000 abstract description 15
- 229930003231 vitamin Natural products 0.000 abstract description 15
- 235000013343 vitamin Nutrition 0.000 abstract description 15
- 239000011782 vitamin Substances 0.000 abstract description 15
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- 229910017053 inorganic salt Inorganic materials 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 3
- 102000004407 Lactalbumin Human genes 0.000 abstract 1
- 108090000942 Lactalbumin Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 18
- 231100000397 ulcer Toxicity 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000003405 preventing effect Effects 0.000 description 7
- 208000007117 Oral Ulcer Diseases 0.000 description 6
- 208000002399 aphthous stomatitis Diseases 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 238000007493 shaping process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229960003657 dexamethasone acetate Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 229960005336 magnesium citrate Drugs 0.000 description 4
- 239000004337 magnesium citrate Substances 0.000 description 4
- 235000002538 magnesium citrate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008723 osmotic stress Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 239000005789 Folpet Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical compound C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 244000000050 gastrointestinal parasite Species 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicine for treating stomatitis, and belongs to the technical field of medicines. The medicine for treating stomatitis provided by the invention comprises lactose, lactalbumin, vitamins and other components. The medicine for treating stomatitis provided by the invention can effectively treat stomatitis, and the effective rate is over 80%. Meanwhile, the ingredients in the medicine are saccharides, inorganic salt and vitamin ingredients which are food-grade ingredients, and the medicine is sweet and delicious, safe to use and free of toxic and side effects.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating stomatitis.
Background
Stomatitis, also known as oral ulcer, is a general term for various oral mucosal inflammations, and its symptoms are mainly mucosal ulceration on the inner side of the lip, cheek, tongue tip, etc. Because of the shallow, dense and sensitive distribution of nerve endings in the oral mucosa, the ulcer surface is usually not more than 0.5cm2But the touch caused by speaking or eating often causes the pain of the patient. Stomatitis can occur at any age, has a prevalence rate of about 10%, and is mainly caused by mechanical trauma of mucosa, endocrine disorder, gastrointestinal dysfunction, constipation, gastrointestinal parasites, insufficient sleep or fatigue, viral and bacterial infection, folic acid or vitamin deficiency, and the like. The exact causes of stomatitis are not completely clear up to now except for mechanical injury, and the occurrence of stomatitis is generally considered by academia as the result of the comprehensive action of multiple elements, so that the mechanism of the medicament is complicated and difficult to be determined up to now.
The medicines and methods for treating stomatitis are many and have different curative effects. In terms of the kind of drug: in the traditional Chinese medicine theory, the treatment theory is developed around 'dryness-heat reducing and fire removing', mainly stomatitis caused by heat rising of liver channel and stomach channel and immunity improvement, such as watermelon frost and Bingpeng powder; western medicine usually adopts the wound surface to directly diminish inflammation, relieve pain, improve immunity or supplement stomatitis caused by trace element deficiency. Such as metronidazole, vitamin B2, chlortetracycline or a healing lotion for local spraying, etc. In addition, the self-healing time of stomatitis is 7-10 days, during which time patients often suffer from pain of eating, touching and brushing teeth. According to clinical observation, the schemes of reducing internal heat and supplementing vitamins are generally used, and the schemes can play a role before and after the self-healing time.
In terms of dosage form: the Chinese medicinal materials include stannum powder and Bingpeng powder, and the western medicines include gargle and patch. The powder is inconvenient to use and is easy to run off along with saliva after being applied to an affected part. For special stomatitis membranes, domestic existing membranes comprise lysozyme membrane, folpet membrane, royal jelly membrane, clotrimazole membrane and the like, and the membrane material is mainly sodium carboxymethylcellulose or polyvinyl alcohol and is a single-layer membrane which is easily dissolved by saliva, the retention time in the oral cavity is usually several minutes, and the effective treatment on ulcer surfaces is difficult to achieve. There are some gargles containing Chinese herbal medicine components for preventing and treating stomatitis on the market, which are not good in taste and can not be eaten, and the gargles are inconvenient to use for preventing stomatitis, and some gargles also have side effects. The time required by some preventive and therapeutic nutrient solutions or beverages is generally longer, and the preventive effect is greater than that of treatment.
In the field of the invention: the 'fruit and vegetable food for treating dental ulcer and the preparation method' 201310135167.4 are prepared by taking the 'cool' fruit and vegetable powder in the theory of traditional Chinese medicine and matching with probiotic powder from the mode of removing dryness and reducing internal heat in the theory of traditional Chinese medicine, and have obvious effect, but the method has slow effect, needs a patient to take 3 times a day, takes 6 days as a treatment course, and is difficult for general patients to insist on the achievement after continuously taking eight treatment courses (namely 48 days). A nutritive liquid for preventing and treating oral ulcer (201410715383.0) is prepared from purified water, vitamins, flavouring and pearl powder through adding vitamins, flavouring and pearl powder, and features its preventing action higher than that of treating it. A vinegar beverage with the function of preventing and treating oral ulcer is 201110040118.3, which is prepared by adding certain medicinal components into acetic acid beverage, and is mainly characterized by the sour and fragrant flavor of the beverage and a certain prevention effect. "method for treating canker sore with patch to accelerate healing and relieve pain" 02822064.1 provides a patch that is applied to the surface of ulcer and can be maintained for a certain period of time using a drug such as licorice, but is applied for 2 hours or more per day. However, liquorice, penicillin and the like are directly used on the oral ulcer surface, which is equivalent to the fact that medicaments are directly contacted with the internal environment of a human body, and the side effect of the medicaments is to be verified. A propolis preparation for treating oral ulcer and its preparing process, 01107701.8, are disclosed, which features that the active components of propolis are extracted by organic solvent, and when it is used, it is applied to ulcer surface by dipping it in cotton bud, and has the main actions of paralysis and pain relief, short acting time, short cure time (about 7 days), and the by-effect of organic solvent on human body. The 'dexamethasone acetate adhesive plaster and the preparation thereof' CN00132507.8 adopt dexamethasone acetate as a medicine patch, the feedback effect on the market is good, but the dexamethasone acetate adhesive plaster is a hormone medicine and cannot be used repeatedly for a long time or many times, and the dexamethasone acetate adhesive plaster can cause osteoporosis, fracture or side effects of low immunity and the like when being taken for a long time by patients with repetitive oral ulcer.
Therefore, the development of a medicament which can rapidly relieve pain, is safe, has no side effect, takes effect quickly and can protect the wound is particularly urgent.
Disclosure of Invention
In view of the above, the invention provides a medicament for treating stomatitis, which is safe, can rapidly relieve pain and has high cure rate.
In order to solve the above problems, the present invention provides the following technical solutions:
the invention provides a medicament for treating stomatitis, which comprises the following active components in parts by weight: 5500-6000 parts of lactose, 1200-1400 parts of whey protein, 800-1000 parts of edible fiber, 45-55 parts of sodium chloride, 115-125 parts of calcium carbonate, 1.15-1.25 parts of ferrous sulfate, 0.85-0.95 part of zinc sulfate, 14.5-15.5 parts of vitamin C, 0.95-1.05 parts of vitamin E, 0.22-0.24 part of riboflavin, 0.00056-0.0006 part of pantothenic acid, 0.060-0.064 part of vitamin A, 0. 30.0028-0.0032 part of vitamin D, 10.0048-0.0052 part of vitamin K, 120.00098-0.0012 part of vitamin B, 0.0028-0.0032 part of vitamin H, 10.00095-0.0015 part of vitamin B, 0.048-0.052 part of calcium carbonate, 0.018-0.022 part of potassium iodide, 0.0048-0.0052 part of magnesium hydrogen phosphate, 0.0018-0.0018 part of potassium citrate, and 0.0029-0.0019 part of potassium phosphate.
Preferably, the composition comprises the following active components in parts by weight: 5700-5900 parts of lactose, 1250-1350 parts of whey protein, 850-950 parts of edible fiber, 48-52 parts of sodium chloride, 118-122 parts of calcium carbonate, 1.18-1.22 parts of ferrous sulfate, 0.88-0.92 part of zinc sulfate, 14.8-15.2 parts of vitamin C, 0.98-1.02 parts of vitamin E, 0.225-0.235 part of riboflavin, 0.00057-0.00059 part of pantothenic acid, 0.061-0.063 part of vitamin A, 30.0029-0.0031 part of vitamin D, 10.0049-0.0051 part of vitamin K, 120.00099-0.0011 part of vitamin B, 0.0029-0.0031 part of vitamin H, 10.00098-0.0013 part of vitamin B, 0.049-0.051 part of calcium carbonate, 0.019-0.021 part of potassium iodide, 0.0049-0.0051 part of magnesium hydrogen phosphate, 0.0019-0.0019 part of potassium citrate, and 0.0020.0019-0.0021 part of potassium citrate and 0.00298 part of potassium phosphate.
Preferably, the dosage form of the medicament comprises a patch and a granule.
Preferably, when the dosage form is a patch, the medicament for treating stomatitis further comprises: 1700-2100 parts of palm oil and 1100-1300 parts of honey.
Preferably, when the dosage form is a patch, the drug content of the patch is 1-2 g/patch.
Preferably, the patch is applied for 3-5 times per day.
Preferably, when the dosage form is electuary, the medicament for treating stomatitis further comprises fructose; the mass ratio of the fructose to the active components is 0.8-1.2: 1.
preferably, the dosage of the medicinal granules is 18-22 g/time.
Preferably, the granule is taken for 3-5 times per day.
Preferably, when the granule is taken after being mixed with water, the mass-to-water volume ratio of the granule is 18-22 g: 100 mL.
The invention provides a medicament for treating stomatitis, which comprises the following active components in parts by weight: 5500-6000 parts of lactose, 1200-1400 parts of whey protein, 800-1000 parts of edible fiber, 45-55 parts of sodium chloride, 115-125 parts of calcium carbonate, 1.15-1.25 parts of ferrous sulfate, 0.85-0.95 part of zinc sulfate, 14.5-15.5 parts of vitamin C, 0.95-1.05 parts of vitamin E, 0.22-0.24 part of riboflavin, 0.00056-0.0006 part of pantothenic acid, 0.060-0.064 part of vitamin A, 0. 30.0028-0.0032 part of vitamin D, 10.0048-0.0052 part of vitamin K, 120.00098-0.0012 part of vitamin B, 0.0028-0.0032 part of vitamin H, 10.00095-0.0015 part of vitamin B, 0.048-0.052 part of calcium carbonate, 0.018-0.022 part of potassium iodide, 0.0048-0.0052 part of magnesium hydrogen phosphate, 0.0018-0.0018 part of potassium citrate, and 0.0029-0.0019 part of potassium phosphate. Lactose is used as the main component, osmotic stress is carried out on a large number of bacteria on the surface of a wound, the bacteria are dehydrated and die, and compared with other saccharides, lactose is easier to hydrolyze, has stronger osmotic ability and better killing effect on the bacteria. Meanwhile, the invention adds elements such as calcium, iron, zinc and the like according to the proportion to help the absorption, regulation and healing of local wound ions and simultaneously supplements a plurality of vitamins necessary for human body, thereby effectively achieving the effect of curing stomatitis and preventing relapse.
Furthermore, when the patch is used by a patient, the patch is stuck on the ulcer surface, and the lactose and the fiber components are condensed into a polymer net structure when meeting water, so that a natural protective patch is formed and firmly adsorbed on the ulcer surface, and can be fixed on the ulcer surface without adding a separate film agent to be slowly released. After the microorganisms (bacteria and the like) on the ulcer surface encounter sugar with high concentration, the microorganisms are dehydrated and die due to the rapid reduction of the extracellular osmotic potential, thereby achieving the aim of diminishing inflammation. Meanwhile, dehydration and death of local wound cells play a further self-protection role, and local nerves are relieved due to signal termination. Vitamins contained in the patch enter a human body through saliva and a wound surface, and the effect of rapidly supplementing the vitamins is achieved; meanwhile, elements such as calcium, iron, zinc and the like are added to help the absorption, regulation and healing of local wound ions. The whole patch is slowly dissolved on the surface due to the secretion of saliva in the oral cavity, and the duration time in the oral cavity can reach 1 hour. The results of the examples show that: the effective rate of the medicament for treating stomatitis provided by the invention is more than 80%. Meanwhile, the components in the formula are food-grade components such as saccharides, inorganic salt, vitamins and the like, the whole process is safe and natural, and the health-care tea is fragrant, sweet and delicious, can quickly shorten the self-healing time, and has no toxic or side effect.
Detailed Description
The invention provides a medicament for treating stomatitis, which comprises the following active components in parts by weight: 5500-6000 parts of lactose, 1200-1400 parts of whey protein, 800-1000 parts of edible fiber, 45-55 parts of sodium chloride, 115-125 parts of calcium carbonate, 1.15-1.25 parts of ferrous sulfate, 0.85-0.95 part of zinc sulfate, 14.5-15.5 parts of vitamin C, 0.95-1.05 parts of vitamin E, 0.22-0.24 part of riboflavin, 0.00056-0.0006 part of pantothenic acid, 0.060-0.064 part of vitamin A, 0. 30.0028-0.0032 part of vitamin D, 10.0048-0.0052 part of vitamin K, 120.00098-0.0012 part of vitamin B, 0.0028-0.0032 part of vitamin H, 10.00095-0.0015 part of vitamin B, 0.048-0.052 part of calcium carbonate, 0.018-0.022 part of potassium iodide, 0.0048-0.0052 part of magnesium hydrogen phosphate, 0.0018-0.0018 part of potassium citrate, and 0.0029-0.0019 part of potassium phosphate.
In the present invention, the medicament for treating stomatitis preferably comprises the following active ingredients in parts by weight: 5700-5900 parts of lactose, 1250-1350 parts of whey protein, 850-950 parts of edible fiber, 48-52 parts of sodium chloride, 118-122 parts of calcium carbonate, 1.18-1.22 parts of ferrous sulfate, 0.88-0.92 part of zinc sulfate, 14.8-15.2 parts of vitamin C, 0.98-1.02 parts of vitamin E, 0.225-0.235 part of riboflavin, 0.00057-0.00059 part of pantothenic acid, 0.061-0.063 part of vitamin A, 30.0029-0.0031 part of vitamin D, 10.0049-0.0051 part of vitamin K, 120.00099-0.0011 part of vitamin B, 0.0029-0.0031 part of vitamin H, 10.00098-0.0013 part of vitamin B, 0.049-0.051 part of calcium carbonate, 0.019-0.021 part of potassium iodide, 0.0049-0.0051 part of magnesium hydrogen phosphate, 0.0019-0.0019 part of potassium citrate, and 0.0020.0019-0.0021 part of potassium citrate; more preferably, it comprises: 5800 parts of lactose, 1300 parts of whey protein, 900 parts of edible fiber, 50 parts of sodium chloride, 120 parts of calcium carbonate, 1.2 parts of ferrous sulfate, 0.9 part of zinc sulfate, 15 parts of vitamin C, 1 parts of vitamin E, 0.23 part of riboflavin, 0.00058 part of pantothenic acid, 0.062 part of vitamin A, 30.003 parts of vitamin D, 10.005 parts of vitamin K, 120.001 parts of vitamin B, 0.003 part of vitamin H, 10.001 parts of vitamin B, 0.05 part of calcium carbonate, 0.02 part of potassium iodide, 0.005 part of magnesium hydrogen phosphate, 0.002 part of potassium citrate, 0.002 part of magnesium citrate and 0.001 part of potassium phosphate.
In the medicament for treating stomatitis, lactose is used as the main component, and performs osmotic stress on a large number of bacteria on the surface of a wound to cause dehydration and death of the bacteria, so that lactose is easier to hydrolyze compared with other saccharides, has stronger osmotic capacity and has better effect of killing the bacteria. Meanwhile, the invention adds the vitamins according to the proportion, meets the requirements of human bodies on the vitamins, is suitable for supplementing the vitamins, and simultaneously adds elements such as calcium, iron, zinc and the like to help the absorption, regulation and healing of local wound ions, thereby effectively achieving the effect of curing and preventing stomatitis.
The source of the active ingredient is not particularly limited in the present invention, and conventional commercial products in the art can be used. The formula medicines in the embodiment of the invention are purchased from the national medicine group, and the brand of honey is Guanshengyuan sophora flower honey.
In the present invention, the dosage form of the medicament for treating stomatitis preferably includes a patch and a granule. In the invention, the patch can be used alone or used together with granules; preferably, the granule and patch are used together.
In the present invention, when the dosage form is a patch, the drug for treating stomatitis preferably further comprises: 1700-2100 parts of palm oil and 1100-1300 parts of honey, more preferably 1800-2000 parts of palm oil and 1150-1250 parts of honey, and most preferably 1900 parts of palm oil and 1200 parts of honey. In the invention, when the dosage form is a patch, the drug content of the patch is preferably 1-2 g/patch, and more preferably 2 g/patch. The frequency of application of the patch is preferably 3-5 patches/day, and more preferably 5 patches/day.
In the invention, the patch is stuck on the ulcer surface, the lactose and the fiber component surface are condensed into a polymer net in the presence of water to form a natural protective patch which is firmly adsorbed on the ulcer surface and can be fixed on the ulcer surface without adding a separate film agent to be slowly released. After the microbial bacteria and the like on the ulcer surface encounter sugar with high concentration, the microbial bacteria and the like lose water and die due to the rapid reduction of the extracellular osmotic potential, thereby achieving the aim of diminishing inflammation. Meanwhile, dehydration and death of local wound cells play a further self-protection role, and local nerves are relieved due to signal termination. Vitamins contained in the patch enter a human body through saliva and a wound surface, and the effect of rapidly supplementing the vitamins is achieved; meanwhile, elements such as calcium, iron, zinc and the like are added to help the absorption, regulation and healing of local wound ions. The whole patch is slowly dissolved on the surface due to saliva secretion in the oral cavity, and the duration time in the oral cavity can reach 1 hour.
In the present invention, when the dosage form is a granule, the medicament for treating stomatitis preferably further comprises fructose; the mass ratio of the fructose to the active components is preferably 0.8-1.2: 1, more preferably 1: 1. In the invention, the dosage of the granule is preferably 18-22 g/time, and more preferably 20 g. The frequency of taking the granules is preferably 4-5 times per day, and more preferably 5 times per day. The infusion is preferably taken at intervals between patch removals.
In the invention, when the granule is taken after being mixed with water, the mass-to-water volume ratio of the granule is preferably 18-22 g: 100mL, more preferably 20 g: 100 mL.
The preparation method of the medicine is not particularly limited, and the components are mixed in a conventional mode.
In order to further illustrate the present invention, the following embodiments are described in detail, but they should not be construed as limiting the scope of the present invention.
Example 1
Weighing 5.5Kg of lactose, 1.4Kg of whey protein, 0.8Kg of edible fiber, 55g of sodium chloride, 115g of calcium carbonate, 1.25g of ferrous sulfate, 0.85g of zinc sulfate, 15.5g of vitamin C, 0.95g of vitamin E, 0.24g of riboflavin, 0.00056g of pantothenic acid, 0.064g of vitamin A, 30.0028g of vitamin D, 10.0052g of vitamin B, 120.00098g of vitamin H, 0.0032g of vitamin B10.00095g, 0.052g of calcium carbonate, 0.018g of potassium iodide, 0.0052g of magnesium hydrogen phosphate, 0.0018g of potassium citrate, 0.0022g of magnesium citrate and 0.0009g of potassium phosphate. Mixing the above materials, stirring with palm oil 1.7Kg and Mel 1.3Kg to obtain paste patch prototype, and shaping the paste patch with a circular patch shaping mold with diameter of 0.8cm and height of 0.1cm to obtain the therapeutic patch.
The raw materials and the addition amount are completely the same as those of the patch except that honey and palm oil are not added, and 1.6Kg of fructose is added and mixed to obtain the electuary.
Example 2
6Kg of lactose, 1.2Kg of whey protein, 1Kg of edible fiber, 45g of sodium chloride, 125g of calcium carbonate, 1.15g of ferrous sulfate, 0.95g of zinc sulfate, 14.5g of vitamin C, 1.05g of vitamin E, 0.22g of riboflavin, 0.0006g of pantothenic acid, 0.060g of vitamin A, 30.0032g of vitamin D, 10.0048g of vitamin K, 120.0012g of vitamin B, 0.0028g of vitamin H, 10.0015g of vitamin B, 0.048g of calcium carbonate, 0.022g of potassium iodide, 0.0048g of magnesium hydrogen phosphate, 0.0022g of potassium citrate, 0.0018g of magnesium citrate and 0.0012g of potassium phosphate are weighed. Mixing the above components, mixing with palm oil 2.1Kg and Mel 1.1Kg, stirring well to obtain paste patch prototype, and shaping the paste patch with circular patch shaping mold with diameter of 0.8cm and height of 0.1cm to obtain the therapeutic patch.
The raw materials and the addition amount are completely the same as those of the patch except that honey and palm oil are not added, and 2.4Kg of fructose is added and mixed to obtain the electuary.
Example 3
Weighing 5.8Kg of lactose, 1.3Kg of whey protein, 0.9Kg of edible fiber, 50g of sodium chloride, 120g of calcium carbonate, 1.2g of ferrous sulfate, 0.9g of zinc sulfate, 15g of vitamin C, 1g of vitamin E, 0.23g of riboflavin, 0.00058g of pantothenic acid, 0.062g of vitamin A, 30.003g of vitamin D, 10.005g of vitamin K, 120.001g of vitamin B, 0.003g of vitamin H, 10.001g of vitamin B, 0.05g of calcium carbonate, 0.02g of potassium iodide, 0.005g of magnesium hydrogen phosphate, 0.002g of potassium citrate, 0.002g of magnesium citrate and 0.001g of potassium phosphate. Mixing the above materials, stirring with palm oil 1.9Kg and Mel 1.2Kg to obtain paste patch prototype, and shaping the paste patch with a circular patch shaping mold with diameter of 0.8cm and height of 0.1cm to obtain the therapeutic patch.
The raw materials and the addition amount are completely the same as those of the patch except that honey and palm oil are not added, and 2Kg of fructose is added and mixed to obtain the electuary.
Example 4
150 volunteers with stomatitis are randomly selected, the members are randomly divided into 3 groups, 50 of the groups are applied to the ulcer surface of a patient, the plaster is kept for 0.5-1 h without eating or drinking water after being applied, the plaster is applied for 5 times every day, and granules are orally taken for 3 times in the gaps of the plaster. The effective rate is counted on the 3 rd day, and the cure rate is counted after the 5 th day and the 7 th day respectively. Specific results are shown in table 1.
TABLE 1 oral inflammation medicine effective rate and cure rate statistics
Note: the number of people who reduce pain and reduce ulcer are crossed by the sectional statistics, and the effective number is that the pain is reduced and the ulcer surface is reduced. The cure rate indicates that the ulcer surface is healed and the pain disappears.
As can be seen from the table 1, the patch of the invention has remarkable effect after using the patch for 3 days, and more than 80% of the pain of people in 3 groups is relieved, which shows that the medicament greatly reduces the pain of patients; the effective rate of pain reduction and ulcer surface reduction of example 3 reached 82%, and examples 1 and 2 reached 70% and 68%, respectively. After 5 days, the effective rate of the embodiment 3 reaches 96 percent, and the cure rate reaches 90 percent; the cure rates of example 1 and example 2 reached 82% and 80%, respectively. The cure rates of examples 1-3 after 7 days were 96%, 94%, and 98%, respectively.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (9)
1. The medicament for treating stomatitis is characterized by comprising the following active components in parts by weight: 5500-6000 parts of lactose, 1200-1400 parts of whey protein, 800-1000 parts of edible fiber, 45-55 parts of sodium chloride, 115-125 parts of calcium carbonate, 1.15-1.25 parts of ferrous sulfate, 0.85-0.95 part of zinc sulfate, 14.5-15.5 parts of vitamin C, 0.95-1.05 parts of vitamin E, 0.22-0.24 part of riboflavin, 0.00056-0.0006 part of pantothenic acid, 0.060-0.064 part of vitamin A, 0. 30.0028-0.0032 part of vitamin D, 10.0048-0.0052 part of vitamin K, 120.00098-0.0012 part of vitamin B, 0.0028-0.0032 part of vitamin H, 10.00095-0.0015 part of vitamin B, 0.048-0.052 part of calcium carbonate, 0.018-0.022 part of potassium iodide, 0.0048-0.0052 part of magnesium hydrogen phosphate, 0.0018-0.0018 part of potassium citrate, 0.0028-0.0019 part of potassium citrate and 0.0022 part of potassium phosphate; the dosage form of the medicine comprises a patch and granules; the patch is used alone or in combination with granule.
2. The medicament for treating stomatitis according to claim 1, comprising the following active ingredients in parts by weight: 5700-5900 parts of lactose, 1250-1350 parts of whey protein, 850-950 parts of edible fiber, 48-52 parts of sodium chloride, 118-122 parts of calcium carbonate, 1.18-1.22 parts of ferrous sulfate, 0.88-0.92 part of zinc sulfate, 14.8-15.2 parts of vitamin C, 0.98-1.02 parts of vitamin E, 0.225-0.235 part of riboflavin, 0.00057-0.00059 part of pantothenic acid, 0.061-0.063 part of vitamin A, 30.0029-0.0031 part of vitamin D, 10.0049-0.0051 part of vitamin K, 120.00099-0.0011 part of vitamin B, 0.0029-0.0031 part of vitamin H, 10.00098-0.0013 part of vitamin B, 0.049-0.051 part of calcium carbonate, 0.019-0.021 part of potassium iodide, 0.0049-0.0051 part of magnesium hydrogen phosphate, 0.0019-0.0019 part of potassium citrate, and 0.0020.0019-0.0021 part of potassium citrate and 0.00298 part of potassium phosphate.
3. The medicament for treating stomatitis according to claim 1, wherein when the dosage form is a patch, the medicament for treating stomatitis further comprises: 1700-2100 parts of palm oil and 1100-1300 parts of honey.
4. The medicament for treating stomatitis according to claim 3, wherein when the dosage form is a patch, the drug content in the patch is 1-2 g/patch.
5. The medicament for treating stomatitis according to claim 3 or 4, wherein the patch is applied for 3 to 5 patches per day.
6. The medicament for treating stomatitis according to claim 1, wherein when the dosage form is a granule, the medicament for treating stomatitis further comprises fructose; the mass ratio of the fructose to the active components is 0.8-1.2: 1.
7. the medicament for treating stomatitis according to claim 6, wherein the granule is administered at a dose of 18-22 g/time.
8. The medicament for treating stomatitis according to claim 6 or 7, wherein the granules are administered 3 to 5 times per day.
9. The medicament for treating stomatitis according to claim 6 or 7, wherein when the granule is taken with water, the mass to water volume ratio of the granule is 18-22 g: 100 mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811503159.XA CN109568340B (en) | 2018-12-10 | 2018-12-10 | Medicine for treating stomatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811503159.XA CN109568340B (en) | 2018-12-10 | 2018-12-10 | Medicine for treating stomatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109568340A CN109568340A (en) | 2019-04-05 |
| CN109568340B true CN109568340B (en) | 2021-01-15 |
Family
ID=65928741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811503159.XA Active CN109568340B (en) | 2018-12-10 | 2018-12-10 | Medicine for treating stomatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109568340B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4406882A (en) * | 1981-02-06 | 1983-09-27 | Biorex Laboratories Limited | Pharmaceutical composition for treating diseases of the oral cavity |
| CN1074920A (en) * | 1991-05-29 | 1993-08-04 | 伯温得药品服务股份有限公司 | Film coating and film coating composition based on cellulose polymer compound and lactose |
| CN1718239A (en) * | 2005-01-28 | 2006-01-11 | 深圳市孚沃德生物技术有限公司 | Oral adhering piece for treating oral exulceratio, and its prepn. method |
| CN101371845A (en) * | 2007-08-23 | 2009-02-25 | 天津药业集团有限公司 | Medicament composition for curing mouth ulcer |
-
2018
- 2018-12-10 CN CN201811503159.XA patent/CN109568340B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4406882A (en) * | 1981-02-06 | 1983-09-27 | Biorex Laboratories Limited | Pharmaceutical composition for treating diseases of the oral cavity |
| CN1074920A (en) * | 1991-05-29 | 1993-08-04 | 伯温得药品服务股份有限公司 | Film coating and film coating composition based on cellulose polymer compound and lactose |
| CN1718239A (en) * | 2005-01-28 | 2006-01-11 | 深圳市孚沃德生物技术有限公司 | Oral adhering piece for treating oral exulceratio, and its prepn. method |
| CN101371845A (en) * | 2007-08-23 | 2009-02-25 | 天津药业集团有限公司 | Medicament composition for curing mouth ulcer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109568340A (en) | 2019-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885857B (en) | Extraction method of periplaneta americana extract for treating peptic ulcer | |
| CN103918865B (en) | A kind of Chinese medicine health-care chewing gum and preparation method thereof | |
| JP2016532446A (en) | Enbu fermented food or beverage composition | |
| CN1060020C (en) | Candy for moistening larynx | |
| CN102784191B (en) | Phyllanthus emblica syrup composition and preparation method thereof | |
| CN109568340B (en) | Medicine for treating stomatitis | |
| CN1907374A (en) | Chinese medicinal composition for treating oral disease | |
| CN104906132B (en) | A kind of plaster for preventing and treating lamb stomatitis | |
| CN110063977B (en) | Radix codonopsis and sea buckthorn composite electuary and application thereof | |
| CN102327304B (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN110787288A (en) | Medical collagen oral ulcer protective gel and preparation method thereof | |
| CN102671058B (en) | Traditional Chinese medicine oral liquid for treatment of vomiting and preparation method thereof | |
| KR20220044055A (en) | Composition for Preventing, Improving, or Treating Alcoholic Gastrointestinal Disease comprising Yeast Extract as an Active Ingredient | |
| CN111529642A (en) | Traditional Chinese medicine stick cream for children and preparation method thereof | |
| CN116115681B (en) | Formula and method for preparing medicament for treating tonsillitis | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| CN110051723A (en) | A kind of fructus hippophae mouthspray and preparation method thereof | |
| CN103948591B (en) | A kind of slimming agents | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system | |
| KR20120064877A (en) | Manufacturing method for diet mesil | |
| CN107320547B (en) | A kind of drug and preparation method thereof for treating the cancer of the esophagus | |
| US20210023127A1 (en) | Method to extract a pharmaceutical composition from a therapeutic compound | |
| CN116570641A (en) | Application of artemisia seed in preparing medicine for treating salivation caused by pig mouth scald | |
| CN117643602A (en) | Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine | |
| CN104784581A (en) | Traditional Chinese medicine preparation for treating traumatic dental ulcer and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |